Chimerix, Inc. (NASDAQ:CMRX - Free Report) - Research analysts at HC Wainwright raised their Q4 2024 earnings per share (EPS) estimates for shares of Chimerix in a note issued to investors on Wednesday, December 11th. HC Wainwright analyst E. White now anticipates that the biopharmaceutical company will earn ($0.24) per share for the quarter, up from their previous forecast of ($0.25). HC Wainwright has a "Buy" rating and a $11.00 price objective on the stock. The consensus estimate for Chimerix's current full-year earnings is ($0.99) per share. HC Wainwright also issued estimates for Chimerix's Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.26) EPS and FY2026 earnings at ($0.99) EPS.
A number of other analysts also recently issued reports on the company. Wedbush reissued an "outperform" rating and set a $6.00 price objective on shares of Chimerix in a research report on Tuesday. StockNews.com raised shares of Chimerix from a "sell" rating to a "hold" rating in a research note on Wednesday, August 21st.
Get Our Latest Research Report on CMRX
Chimerix Price Performance
NASDAQ:CMRX traded up $0.06 on Friday, reaching $3.00. The company's stock had a trading volume of 1,784,124 shares, compared to its average volume of 1,249,054. Chimerix has a 12-month low of $0.75 and a 12-month high of $3.39. The stock has a 50 day moving average price of $1.03 and a 200 day moving average price of $0.94.
Hedge Funds Weigh In On Chimerix
A number of hedge funds and other institutional investors have recently bought and sold shares of CMRX. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Chimerix by 66.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company's stock valued at $321,000 after acquiring an additional 138,098 shares in the last quarter. Marshall Wace LLP purchased a new stake in Chimerix during the 2nd quarter worth about $137,000. Finally, Valeo Financial Advisors LLC raised its position in Chimerix by 566.9% in the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company's stock valued at $76,000 after purchasing an additional 69,505 shares in the last quarter. 45.42% of the stock is currently owned by hedge funds and other institutional investors.
Chimerix Company Profile
(
Get Free Report)
Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.
Further Reading
Before you consider Chimerix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chimerix wasn't on the list.
While Chimerix currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
